Stockscreener 앱 받기
3.46
23.06%
0.62
전일 마감가:
$2.84
열려 있는:
$3.13
하루 거래량:
6.18M
Relative Volume:
5.78
시가총액:
$250.93M
수익:
-
순이익/손실:
$-292.19M
주가수익비율:
-0.7621
EPS:
-4.54
순현금흐름:
$-208.41M
1주 성능:
+155.11%
1개월 성능:
+153.26%
6개월 성능:
+166.79%
1년 성능:
+25.72%
1일 변동 폭
$3.06
$3.755
1주일 범위
$1.33
$3.755
52주 변동 폭
$1.01
$3.755
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
명칭
Zentalis Pharmaceuticals Inc
전화
(858) 263-4333
주소
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
3.4731 | 205.19M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.29 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
800.48 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.39 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.31 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
339.38 | 35.45B | 4.98B | 69.59M | 525.67M | 0.5197 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-12 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2024-06-20 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-06-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2024-06-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 개시 | Cowen | Outperform |
| 2022-04-06 | 개시 | Wells Fargo | Overweight |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-29 | 개시 | Oppenheimer | Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-01-20 | 개시 | Wedbush | Outperform |
| 2020-09-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 개시 | H.C. Wainwright | Buy |
| 2020-04-28 | 개시 | Guggenheim | Buy |
| 2020-04-28 | 개시 | Jefferies | Buy |
| 2020-04-28 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 개시 | SVB Leerink | Outperform |
모두보기
Zentalis Pharmaceuticals Inc 주식(ZNTL)의 최신 뉴스
Zentalis Pharmaceuticals Stock (ZNTL) Opinions on Azenosertib Development Update - Quiver Quantitative
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutPortfolio Update Summary & Trade Opportunity Analysis Reports - ulpravda.ru
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m By Investing.com - Investing.com Canada
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m - Investing.com
Is Zentalis Pharmaceuticals Inc. stock a top pick in earnings seasonWeekly Stock Report & Real-Time Volume Triggers - ulpravda.ru
Why analysts remain bullish on Zentalis Pharmaceuticals Inc. stockOil Prices & Risk Managed Investment Strategies - ulpravda.ru
Will Zentalis Pharmaceuticals Inc. stock outperform tech sector in 2025Insider Selling & Expert Curated Trade Ideas - ulpravda.ru
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Yahoo Finance
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained) - TipRanks
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Zentalis Eyes A Pivotal 2026 As Azenosertib Advances Toward Potential Accelerated Approval - Nasdaq
ZNTL Pharmaceuticals Updates on Azenosertib Development - GuruFocus
What drives Zentalis Pharmaceuticals Inc stock priceGap Fill Strategies & Double Or Triple Capital - earlytimes.in
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - MarketScreener
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Hold” by Brokerages - Defense World
Will Zentalis Pharmaceuticals Inc. stock outperform growth indexes2025 Price Action Summary & Verified Swing Trading Watchlists - Улправда
Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Profit Recap & Free Growth Oriented Trading Recommendations - Bölüm Sonu Canavarı
Will Zentalis Pharmaceuticals Inc. stock see PE expansionWeekly Risk Report & AI Powered Buy/Sell Recommendations - DonanımHaber
Why Zentalis Pharmaceuticals Inc. stock is favored by top institutions2025 Key Highlights & Consistent Income Trade Ideas - Улправда
Zentalis Pharmaceuticals Earnings Notes - Trefis
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell - GlobeNewswire Inc.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Matrix Capital Management Comp Sells 7,500,000 Shares of Stock - Defense World
Insider Selling: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Sells 7,500,000 Shares of Stock - MarketBeat
Zentalis Pharmaceuticals (ZNTL) director reports 7,500,000 share sale - Stock Titan
[8-K] Zentalis Pharmaceuticals, Inc. Reports Material Event | ZNTL SEC FilingForm 8-K - Stock Titan
Oppenheimer cuts Zentalis stock target to $10, maintains rating - MSN
Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market - Seeking Alpha
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharma (ZNTL) Stock Analysis Report | Financials & Insights - Benzinga
Can Zentalis Pharmaceuticals Inc. stock surprise with earnings upside2025 Volume Leaders & Reliable Entry Point Alerts - Newser
An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - setenews.com
We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate - Yahoo Finance
Is Zentalis Pharmaceuticals Inc. stock a safe haven asset2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
New Highs: Will Zentalis Pharmaceuticals Inc stock outperform growth indexesMarket Risk Report & Risk Controlled Stock Pick Alerts - BỘ NỘI VỤ
Is Zentalis Pharmaceuticals Inc. stock safe for conservative investorsJuly 2025 Summary & Free Daily Entry Point Trade Alerts - Newser
Are Bears Losing Grip on Artson LimitedMarket Capitalization Trends & Reduce Losses With Smart Exit Strategies - earlytimes.in
Is Zentalis Pharmaceuticals Inc. stock trading near support levels2025 Pullback Review & Long-Term Growth Stock Strategies - BỘ NỘI VỤ
Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - Setenews
Connor Clark & Lunn Investment Management Ltd. Decreases Stake in Zentalis Pharmaceuticals, Inc. $ZNTL - Defense World
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
What indicators show strength in Zentalis Pharmaceuticals Inc.Portfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
Is Zentalis Pharmaceuticals Inc. stock in correction or buying zoneMarket Volume Summary & Free Verified High Yield Trade Plans - newser.com
Why analysts upgrade Zentalis Pharmaceuticals Inc. stockEarnings Performance Report & Weekly Setup with High ROI Potential - newser.com
Why Zentalis Pharmaceuticals Inc. stock is in analyst buy zone2025 Analyst Calls & AI Driven Stock Reports - newser.com
Is Zentalis Pharmaceuticals Inc. forming a bottoming base2025 Top Decliners & Reliable Price Breakout Alerts - newser.com
Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha
Multi asset correlation models including Zentalis Pharmaceuticals Inc.Earnings Beat & Weekly High Conviction Trade Ideas - newser.com
Zentalis Pharmaceuticals Inc (ZNTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Zentalis Pharmaceuticals Inc 주식 (ZNTL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Matrix Capital Management Comp | 10% Owner |
Dec 15 '25 |
Sale |
1.33 |
7,500,000 |
9,975,000 |
6,459,973 |
| Myers Scott Dunseth | Director |
Apr 30 '25 |
Buy |
1.40 |
21,000 |
29,373 |
281,192 |
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
0.37%
자본화:
|
볼륨(24시간):